Skip to main content

Table 2 Correlation analysis between COPA expression and clinicopathological characteristics

From: Identification of COPA as a potential prognostic biomarker and pharmacological intervention target of cervical cancer by quantitative proteomics and experimental verification

Clinicopathological characteristics Cervical AC (n = 85) Cervical SCC (n = 55)
Score 0 n (%) Score 1 n (%) Score 2 +  n (%)3 P value Score 0 n (%) Score 1 n (%) Score 2 +  n (%)3 p value
Stage         
 I 1 (1.2) 7 (8.2) 50 (58.8) 0.455 2 (3.6) 18 (32.7) 27 (49.1) 0.536
 II 0 (0) 0 (0) 20 (23.5) 0 (0) 1 (1.8) 5 (9.1)
 III 0 (0) 0 (0) 7 (8.2) 0 (0) 0 (0) 2 (3.6)
PI         
 Yes 0 (0) 0 (0) 2 (2.4) 1 0 (0) 1 (1.8) 1 (1.8) 1
 No 1 (1.2) 7 (8.2) 75 (88.2) 2 (3.6) 18 (32.7) 33 (60.0)
LNM         
 Yes 0 (0) 1 (1.2) 10 (11.8) 1 1 (1.8) 2 (3.6) 6 (10.9) 0.331
 No 1 (1.2) 6 (7.1) 67 (78.8) 1 (1.8) 17 (30.9) 28 (50.9)
TS         
 ≥ 2 cm 1 (1.2) 1 (1.2) 46 (54.1) 0.040 2 (3.6) 14 (25.5) 24 (43.6) 1
 < 2 cm 0 (0) 6 (7.1) 31 (36.5) 0 (0) 5 (9.1) 10 (18.1)
DSI         
 Yes 0 (0) 3 (3.5) 43 (50.6) 0.558 2 (3.6) 14 (25.5) 23 (41.8) 0.880
 No 1 (1.2) 4 (4.7) 34 (40.0) 0 (0) 5 (9.1) 11 (20.0)
LVSI         
 Yes 0 (0) 1 (1.2) 14 (16.5) 1 1 (1.8) 6 (10.9) 16 (29.1) 0.551
 No 1 (1.2) 6 (7.1) 63 (74.1) 1 (1.8) 13 (23.6) 18 (32.7)
  1. Stage, FIGO staging of carcinoma of the cervix uteri (2018); TS, Tumour size; DSI, Deep stromal invasion; LVSI, Lymphatic vascular space involvement; LNM, Lymph node metastasis. p < 0.05 is marked with asterisk